GMAB vs INCY
Genmab A/S and Incyte, both Healthcare
Incyte is the larger company at $20B against $16B. Over the past year INCY returned +31% against +31% for GMAB. The RyuScore puts GMAB ahead, 84 against 82 out of 100.
| Figure | GMAB | INCY |
|---|---|---|
| Last close | $37.06 | $113 |
| Market cap | $16B | $20B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 15.9 |
| 1-year return | +31% | +31% |
| 5-year return | -15% | +56% |
| RyuScoresector-relative, 1–10 | 84/100 | 82/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.